Generally Accepted Accounting Principles (GAAP). 26, 2016, Horizon Pharma agreed to pay Express Scripts $65 million as part of a litigation settlement, which was recorded as a one-time reduction to GAAP net sales for the three months ended Sept. (1) The fourth-quarter and full-year 2016 net losses were primarily impacted by the impairment of in-process research and development and other wind- down costs and charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia and acquisition-related costs primarily related to the acquisition of Raptor Pharmaceutical Corp. (in millions except for per share amounts and percentages) “Our performance and continued strategic acquisitions have strengthened and diversified the Company and positioned us well to deliver on our growth objectives over the long term.” Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “We delivered a strong fourth quarter and another exceptional year of performance driven by continued commercial execution and the completion of two transformative acquisitions that bolster our rapidly expanding rare disease business,” said Timothy P.
27, 2017 (GLOBE NEWSWIRE) - Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its fourth-quarter and full-year 2016 financial results today and provided its full-year 2017 net sales and adjusted EBITDA guidance. Full-Year 2017 Net Sales Guidance of $1.24 Billion to $1.29 Billion įull-Year 2017 Adjusted EBITDA Guidance of $525 Million to $575 Million -ĭUBLIN, Ireland, Feb. Year-End 2016 Cash Balance of $509.1 Million. Full-Year 2016 Operating Cash Flow of $369.5 Million įull-Year 2016 Non-GAAP Operating Cash Flow of $452.9 Million Full-Year 2016 Net Loss of $166.8 Million (1) Adjusted EBITDA of $470.7 Million – Full-Year 2016 Net Sales of $981.1 Million (2) įull-Year 2016 Non-GAAP Adjusted Net Sales of $1,046.1 Million (2). Fourth-Quarter 2016 Operating Cash Flow of $139.2 Million įourth-Quarter 2016 Non-GAAP Operating Cash Flow of $193.1 Million.
Fourth-Quarter 2016 Net Loss of $130.5 Million (1) Adjusted EBITDA of $136.4 Million. Fourth-Quarter 2016 Net Sales of $310.3 Million Up 27 Percent.
0 kommentar(er)
